News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Octapharma AG Sponsors Symposium “Spotlight On The Human Factor: Building A Foundation For The Future Of Haemophilia A Management" At 2014 WFH World Congress In Melbourne, Australia


5/27/2014 7:08:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Octapharma sponsored the symposium "Spotlight on the human factor: building a foundation for the future of haemophilia A management" during the World Federation of Hemophilia (WFH) World Congress in Melbourne, Australia on Monday May 12th 2014.

Major challenges in current haemophilia treatment include the development of inhibitors and the need for frequent venous access for FVIII injection. Octapharma’s human cell line recombinant FVIII (Human-cl rhFVIII) is a new- generation rFVIII derived from a human cell line without addition of animal derived proteins.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES